The Nordic Pharma Group Announces a Strategic Collaboration With Nippon Kayaku on Spanidin(R) (Gusperimus)

PARIS, December 22, 2010 - Nippon Kayaku (NK) and the Nordic Pharma Group (Nordic) have
signed a licensing agreement under which NK grants exclusive rights to NORDIC
for the development and commercialisation of Spanidin(R) (gusperimus) in
selected territories outside of Japan, including Europe.

Spanidin(R) is an immunosuppressive agent developed and
commercialised in Japan by NK in acute and accelerated rejection crisis after
renal transplantation. The product has obtained promising results and orphan
medicinal product status in Europe for the treatment of Wegener's
Granulomatosis (WG).

Under this agreement, Nordic will design and execute the
global clinical development of Spanidin(R), which includes a pivotal,
comparative Phase III study for these patients suffering from WG relapse.
Nordic will also be responsible for the regulatory filing and
commercialisation of the product in the relevant countries. NK will ensure
production of the active ingredient until registration and beyond.

Spanidin(R) has the potential to offer a treatment for
relapsing WG patients, who currently have no approved drug to cure their
disease.

With this new agreement, Nordic is actively pursuing its
strategy to bring innovative drugs to the market in specialized therapeutic
areas that have specific, unmet medical needs.

About the Nordic Group

The Nordic Group is a privately-owned, fast-growing,
fully-integrated, pan-European Pharmaceutical Group that places strong
emphasis on the development and commercialisation of niche hospital and
orphan products and services that cater to the special needs of each client
and patient. Nordic has 2 main platforms of core competencies:

    - Marketing & Sales of Speciality pharmaceuticals throughout 13
      countries in Europe (Nordic Pharma, Nordic Drugs)

    - Specialised Pharmaceutical Services, which focus on Product
      Development, Manufacturing, Supply Logistics and Regulatory activities
      (Prague Clinical Services, QPharma, Disphar)

Since its creation, Nordic has enjoyed an average of 20%
growth in revenues and pursues its expansion through organic growth and
strategic collaborations.

Additional information can be obtained by visiting Nordic
Group's Website at www.nordicpharmagroup.com

About Nippon Kayaku

Founded in 1916, Nippon Kayaku now focuses on pharmaceuticals,
functional chemicals, and safety systems with over $1.7 Billion in revenues.
In its Pharmaceutical Division, Nippon Kayaku manufactures and sells
anti-cancer drugs, cardiovascular drugs, immunosuppressants, and other
pharmaceuticals and diagnostics for prescription. In the anti-cancer drug
field in particular, Nippon Kayaku offers a line up of 26 anti-cancer drugs
and 6 supportive drugs, and is at the top level worldwide both in terms of
technology and business performance. Nippon Kayaku works with cutting-edge
technologies, and conducts clinical development for pharmaceutical DDSs (Drug
Delivery Systems) with nanotechnology.

Additional information can be obtained by visiting Nippon
Kayaku's Website at www.nipponkayaku.co.jp/english/

Contact:

Hans Schram, CEO & Managing Director, info@nordicpharma.com

Stéphane Altaba, Director Corp. Bus. Dev., busdev@nordicpharma.com

Contact: Hans Schram, CEO & Managing Director, info at nordicpharma.com. Stéphane Altaba, Director Corp. Bus. Dev., busdev at nordicpharma.com. Tel: +33-153-63-22-70